Omar Castaneda Puglianini
A5047518602- Multiple Myeloma Research and Treatments
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- RNA Interference and Gene Delivery
- Protein Degradation and Inhibitors
- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- vaccines and immunoinformatics approaches
- Viral Infectious Diseases and Gene Expression in Insects
- Lymphoma Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Cancer Mechanisms and Therapy
- Acute Myeloid Leukemia Research
- Biosimilars and Bioanalytical Methods
- T-cell and B-cell Immunology
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Synthesis and Biological Evaluation
- Monoclonal and Polyclonal Antibodies Research
- Nanowire Synthesis and Applications
- Semiconductor materials and devices
- Mesenchymal stem cell research
- Pharmacological Effects and Toxicity Studies
- Advanced Breast Cancer Therapies
Moffitt Cancer Center
2019-2025
VCU Massey Comprehensive Cancer Center
2022
University of South Florida
2022
Virginia Commonwealth University
2020-2021
Abstract Most patients with multiple myeloma experience disease relapse after treatment a B-cell maturation antigen-targeted therapy (BCMA-TT), and data describing outcomes for treated sequential BCMA-TT are limited. We analyzed clinical infused standard-of-care idecabtagene vicleucel, an anti-BCMA chimeric antigen receptor (CAR) T-cell therapy, at 11 US medical centers. A total of 50 prior exposure (38 antibody-drug conjugate, 7 bispecific, 5 CAR T) 153 no were ide-cel, median follow-up...
Idecabtagene vicleucel (ide-cel) was FDA-approved in March 2021 for the treatment of relapsed/refractory multiple myeloma after 4 lines therapy. On KarMMa trial, grade ≥ 3 cytopenias and infections were common. We sought to characterize within 100 days ide-cel standard-of-care (SOC) setting. This multi-center retrospective study included 52 patients who received SOC ide-cel; 47 reached day-90 follow-up. Data censored at day 100. Grade cytopenia present among 65% 30 40% 90. Granulocyte colony...
While response rates and survival outcomes have been very promising for idecabtagene vicleucel (ide-cel), a proportion of patients do not respond or relapse early after this B-cell maturation antigen (BCMA) targeted CAR T-cell therapy. Understanding the characteristics these is important patient selection development novel strategies to improve outcomes. We evaluated factors associated with progression (progression death due myeloma ≤ 3 months T infusion) in treated standard care ide-cel at...
PURPOSE Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), two B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapies have demonstrated remarkable efficacy in relapsed/refractory multiple myeloma (RRMM). We compare safety, efficacy, survival among patients with RRMM treated standard-of-care (SOC) ide-cel or cilta-cel. METHODS Data were from a retrospective chart review of leukapheresed by December 31, 2022, the intent to receive SOC...
PURPOSE This phase I-Ib trial evaluated a novel CD40L blocking antibody, BMS-986004, for the prevention of graft-versus-host disease (GVHD) after unrelated donor allogeneic hematopoietic cell transplantation (HCT). PATIENTS AND METHODS A total 34 patients were treated at three centers. The safety and biologic activity single-dose BMS-986004 (675 mg [n = 6] 1,500 6]; one-time dose) evaluated. Safety prolonged dosing was then examined in separate cohorts (drug administration every 2 weeks × 3...
Abstract Idecabtagene vicleucel (ide-cel) is a type of B-cell maturation antigen (BCMA)–targeting chimeric receptor T-cell (CAR-T) approved for the treatment relapsed and refractory multiple myeloma (RRMM). Currently, incidence cardiac events associated with ide-cel remains unclear. This was retrospective single-center observational study patients treated RRMM. We included all consecutive who received standard-of-care at least 1-month follow-up. Baseline clinical risk factors, safety...
Idecabtagene vicleucel (ide-cel) was the first chimeric antigen receptor T-cell therapy to gain US Food and Drug Administration approval for patients with relapsed/refractory multiple myeloma (RRMM). The clinical outcomes of standard care (SOC) ide-cel in racially ethnically diverse populations have been understudied. This study pooled data from 207 RRMM (28% racial ethnic minority groups) treated SOC across 11 institutions examine differences incidence toxicities adverse events, response...
Abstract Purpose: We investigated whether a dendritic cell (DC) vaccine transduced with an adenoviral vector encoded full-length survivin (Ad-S), mutations neutralizing its antiapoptotic function, could safely generate immune response and deepen clinical responses when administered before after autologous stem transplant (ASCT) for multiple myeloma. Patients Methods: This phase I first-in-human trial (NCT02851056) evaluated the safety of DC:Ad-S in newly diagnosed myeloma not having achieved...
8013 Background: Ide-cel is an FDA-approved treatment for RRMM patients (pts). However, there limited data on how BT disease control during its manufacturing process affects clinical outcomes. Methods: Eleven US academic centers contributed to this analysis without involvement from the manufacturer. By 5/1/2022, 235 pts had undergone leukapheresis, with 214 infused a median follow up of 9 months (mos). was given between leukapheresis and CAR-T infusion. Results: In analysis, 79% (n = 170)...
12052 Background: Multiple myeloma is a disease of older adults with median age at diagnosis 68 years (y). Patients (pts) receiving chimeric antigen receptor T-cell (CAR-T) therapy for relapsed/refractory MM (RRMM) often experience detrimental effects due to frailty, comorbidity, and cumulative toxicities. In this study, we evaluated the prevalence impact defined by simplified frailty score, (SFS; Facon et al, Leukemia 2020), immuno-nutritional status, using Glasgow-prognostic score (GPS;...